Nextcure to present trial in progress poster for nc525 at the 2022 american society of hematology (ash) annual meeting

Beltsville, md., nov. 03, 2022 (globe newswire) -- nextcure, inc. (nasdaq: nxtc), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that clinical trial investigator nicholas short, m.d., assistant professor in the department of leukemia at the university of texas md anderson cancer center in houston, texas, will present a trials in progress poster for nc525, a novel first-in-class immunomedicine, at the american society of hematology (ash) annual meeting in new orleans. nc525 is a humanized monoclonal antibody that specifically binds to leukocyte-associated immunoglobulin-like receptor 1 (lair-1) and is being developed for the treatment of advanced myeloid leukemia (aml).
NXTC Ratings Summary
NXTC Quant Ranking